SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, today announced that it will participate in the following investor conferences in September.
H.C. Wainwright 25th Annual Global Investment Conference
Date: September 11-13, 2023
Location: Lotte New York Palace Hotel, New York, NY
Date and Time of Presentation: Available September 11, 2023, at 7:00 a.m. ET
Format: Corporate Presentation and 1x1 meetings
Webcast Link: https://journey.ct.events/view/3eb50cf4-1561-4363-8e78-ac2c56092fb6
Cantor Fitzgerald Annual Global Healthcare Conference
Dates: September 26-28, 2023
Location: InterContinental Barclay Hotel, New York, NY
Date and Time of Panel Presentation: September 26, 2023, at 11:35 a.m. ET
Format: Panel Presentation and 1x1 meetings
A webcast of the presentations, if available, will be available on the “Events” section of the Clene website.
About Clene
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
Contacts:
Media Contact | Investor Contact |
Ignacio Guerrero-Ros, Ph.D., or David Schull | Kevin Gardner |
Russo Partners, LLC | LifeSci Advisors |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
This email address is being protected from spambots. You need JavaScript enabled to view it. | 617-283-2856 |
Last Trade: | US$0.34 |
Daily Change: | -0.0065 -1.88 |
Daily Volume: | 116,348 |
Market Cap: | US$43.670M |
March 07, 2024 February 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB